What do systematic reviews say?

CBT vs other experimental control

• Cognitive behavioural therapy for tinnitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 95 participants
  Very low

Pazopanib vs sunitinib (targeted agent versus targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 467 participants
  Low

Fexofenadine 120 mg/d vs placebo (1‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Loratadine 10 mg vs placebo (4‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Loratadine 10 mg vs placebo (2‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Cetirizine 10 mg/d vs placebo (4‐week intervention)

The review found no eligible studies for this question.

• Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Behavioural activation vs third‐wave CBT

• Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 81 participants
  Low

Behavioural activation vs waiting list control

• Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Low

Behavioural activation vs no treatment

• Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 118 participants
  High

Multi‐component intervention vs control

• Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD) 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 374 participants
  Low

CBT vs no treatment or waiting list

• Cognitive behavioural therapy for tinnitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 537 participants
  Low

Behavioural activation vs treatment

• Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 1299 participants
  Very low

Behavioural activation vs CBT

• Behavioural activation therapy for depression in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 268 participants
  Moderate

CBT vs other experimental control

• Cognitive behavioural therapy for tinnitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  12 studies · 966 participants
  Low

Intervention not reported

The intervention showed no clear difference in health‐related quality of life (HRQOL) disease‐specific HRQOL (low certainty).

• Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  17 participants
  Low

Intervention not reported

• Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Moderate

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Spironolactone 100 mg vs placebo

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found